Vanguard Group Inc. Has $155.97 Million Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Vanguard Group Inc. lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 0.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,699,353 shares of the company’s stock after selling 34,256 shares during the period. Vanguard Group Inc. owned 8.18% of Harmony Biosciences worth $155,972,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in HRMY. Deep Track Capital LP acquired a new stake in Harmony Biosciences during the 4th quarter worth approximately $49,894,000. LSV Asset Management boosted its position in Harmony Biosciences by 25.0% during the 1st quarter. LSV Asset Management now owns 1,194,961 shares of the company’s stock worth $39,661,000 after buying an additional 238,744 shares during the period. Allianz Asset Management GmbH boosted its position in Harmony Biosciences by 1,709.0% during the 1st quarter. Allianz Asset Management GmbH now owns 220,704 shares of the company’s stock worth $7,325,000 after buying an additional 208,504 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Harmony Biosciences by 66.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company’s stock worth $17,205,000 after buying an additional 200,000 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Harmony Biosciences by 15.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,213,029 shares of the company’s stock worth $41,739,000 after buying an additional 160,490 shares during the period. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Stock Performance

NASDAQ:HRMY opened at $36.63 on Thursday. The company has a fifty day moving average of $34.30 and a 200-day moving average of $33.71. The firm has a market capitalization of $2.11 billion, a P/E ratio of 11.82, a P/E/G ratio of 0.43 and a beta of 0.84. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing the consensus estimate of $0.78 by ($0.10). The company had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The business’s revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.05 EPS. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HRMY. Mizuho lifted their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an “outperform” rating in a research report on Thursday, May 15th. Oppenheimer started coverage on shares of Harmony Biosciences in a research report on Monday, June 2nd. They set an “outperform” rating and a $61.00 target price for the company. Cantor Fitzgerald raised shares of Harmony Biosciences to a “strong-buy” rating in a research report on Tuesday, May 13th. Needham & Company LLC reissued a “buy” rating and set a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. Finally, Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $51.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.